These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15051744)

  • 1. Influence of azimilide on CYP2C19-mediated metabolism.
    El Mouelhi M; Worley DJ; Kuzmak B; Destefano AJ; Thompson GA
    J Clin Pharmacol; 2004 Apr; 44(4):373-8. PubMed ID: 15051744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects.
    El Mouelhi M; Worley DJ; Kuzmak B; Destefano AJ; Thompson GA
    Br J Clin Pharmacol; 2004 Dec; 58(6):641-7. PubMed ID: 15563362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride.
    Corey A; Agnew J; Bao J; Bryson P; Comer P; Griffith S; Li J
    J Clin Pharmacol; 1997 Oct; 37(10):946-53. PubMed ID: 9505986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
    Yu KS; Yim DS; Cho JY; Park SS; Park JY; Lee KH; Jang IJ; Yi SY; Bae KS; Shin SG
    Clin Pharmacol Ther; 2001 Apr; 69(4):266-73. PubMed ID: 11309556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration.
    Corey AE; Agnew JR; Valentine SN; Parekh NJ; Powell JH; Thompson GA
    Br J Clin Pharmacol; 2002 Nov; 54(5):449-52. PubMed ID: 12445022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation.
    Corey AE; Agnew JR; Valentine SN; Nesbitt JD; Wagner DL; Powell JH; Thompson GA
    J Clin Pharmacol; 1999 Dec; 39(12):1272-6. PubMed ID: 10586393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
    Tybring G; Böttiger Y; Widén J; Bertilsson L
    Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin.
    Toothaker RD; Corey AE; Valentine SN; Agnew JR; Parekh N; Moehrke W; Thompson GA; Powell JH
    J Clin Pharmacol; 2005 Jul; 45(7):773-80. PubMed ID: 15951467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative oral bioavailability of azimilide dihydrochloride in the fed and fasted states.
    Corey AE; Agnew JR; Valentine SN; Nesbitt JD; Wagner DL; Powell JH; Thompson GA
    Br J Clin Pharmacol; 2000 Mar; 49(3):279-82. PubMed ID: 10718785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide.
    Phillips L; Grasela TH; Agnew JR; Ludwig EA; Thompson GA
    Clin Pharmacol Ther; 2001 Oct; 70(4):370-83. PubMed ID: 11673753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic profile of azimilide in man: in vivo and in vitro evaluations.
    Riley P; Figary PC; Entwisle JR; Roe AL; Thompson GA; Ohashi R; Ohashi N; Moorehead TJ
    J Pharm Sci; 2005 Sep; 94(9):2084-95. PubMed ID: 16052551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
    Tassaneeyakul W; Vannaprasaht S; Yamazoe Y
    Br J Clin Pharmacol; 2000 Feb; 49(2):139-44. PubMed ID: 10671908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects.
    Palovaara S; Tybring G; Laine K
    Br J Clin Pharmacol; 2003 Aug; 56(2):232-7. PubMed ID: 12895199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride.
    Corey A; Agnew J; Brum J; Parekh N; Valentine S; Williams M
    J Clin Pharmacol; 1999 Dec; 39(12):1263-71. PubMed ID: 10586392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
    Chen BL; Chen Y; Tu JH; Li YL; Zhang W; Li Q; Fan L; Tan ZR; Hu DL; Wang D; Wang LS; Ouyang DS; Zhou HH
    J Clin Pharmacol; 2009 May; 49(5):574-81. PubMed ID: 19398604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism.
    Tateishi T; Kumai T; Watanabe M; Nakura H; Tanaka M; Kobayashi S
    Br J Clin Pharmacol; 1999 Apr; 47(4):454-7. PubMed ID: 10233213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artemisinin induces omeprazole metabolism in human beings.
    Svensson US; Ashton M; Trinh NH; Bertilsson L; Dinh XH; Nguyen VH; Nguyen TN; Nguyen DS; Lykkesfeldt J; Le DC
    Clin Pharmacol Ther; 1998 Aug; 64(2):160-7. PubMed ID: 9728896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans.
    Gonzalez HM; Romero EM; Peregrina AA; de J Chávez T; Escobar-Islas E; Lozano F; Hoyo-Vadillo C
    J Clin Pharmacol; 2003 Nov; 43(11):1211-5. PubMed ID: 14551175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.